Abstract:Background: The ubiquitin-specific protease 2 (USP2) is a member of the USP family known as deubiquitinating enzymes, which play a critical role in the protection of prostate cancer from apoptosis. Until now, the role of USP2 in breast cancer has not been very clear. Material and methods: First, We identified USP2 expression levels in human breast tumors using immunohistochemistry. 121 primary breast cancers, 13 paired normal tissues and 13 paired distant metastatic lesions were assessed. Survival analysis was performed using log-rank test and Cox regression hazard model. Secondly, we performed matrigel migration and invasion assays with USP2-silenced and USP2-overexpressed breast cancer cell lines to understand the basic mechanism. Protein expression was analyzed by western blot. Results: In 121 human breast tumors, cytoplasmic positive immunostaining of USP2 was detected in tumorous glands; whereas in normal breast epithelium, its expression was negative. Moreover USP2 was overexpressed in distant metastatic lesion compared with primary breast cancer. More importantly, positive USP2 immunostaining was correlated with the triple negative breast cancer (TNBC) subtype. Survival analyses demonstrated that positive USP2 is a poor prognostic factor for disease-free survival. By in vitro study we found that silencing of USP2 by siRNA decreased migration and invasion in LM2-4175 and SCP46, two metastatic subclones of the TNBC cell line MDA-MB-231, associated with decreased matrix metalloproteinase 2 (MMP2) expression. On the other hand, overexpression of USP2 in MDA-MB-468 and MDA-MB-231 cells enhanced migration and invasion, and also increased the expression of MMP2. Conclusions: These clinical and preclinical data confirm that higher USP2 expression is associated with poorer survival of breast cancer patients and invasiveness of TNBC cells. Our results suggest the clinical value of USP2 as a new therapeutic target in TNBC.

USP4 Promotes Invasion of Breast Cancer Cells Via Relaxin/TGF-β1/Smad2/MMP-9 Signal.

USP4 is regulated by Akt phosphorylation and deubiquitylates TGF-beta type I receptor

USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-[beta] type I receptor

USP4 is Regulated by AKT Phosphorylation and Directly Deubiquitylates TGF-β Type I Receptor

USP2 Promotes Progression in Triple Negative Breast Cancer

USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1

A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis

Inhibition of Ubiquitin-specific Protease 4 Attenuates Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells Via Transforming Growth Factor Beta Receptor Type I

Downregulation of Ubiquitin-Specific Protease 14 (USP14) Inhibits Breast Cancer Cell Proliferation and Metastasis, but Promotes Apoptosis

Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 is Required for Potentiating Colorectal Oncogenesis.

USP2 promotes cell migration and invasion in triple negative breast cancer cell lines

USP2a Supports Metastasis by Tuning TGF-β Signaling.

Effects of ubiquitin-specific proteases 2-69 on proliferation of breast cancer cells

USP1 Inhibition Destabilizes KPNA2 and Suppresses Breast Cancer Metastasis

Usp4 Inhibits Smad4 Monoubiquitination and Promotes Activin and Bmp Signaling

Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC

USP22 Drives Colorectal Cancer Invasion and Metastasis Via Epithelial-Mesenchymal Transition by Activating AP4

USP14 Promotes the Proliferation of Cervical Cancer Via Upregulating Β-Catenin

USP10 promotes cell proliferation, migration, and invasion in NSCLC through deubiquitination and stabilization of EIF4G1

Deubiquitinating enzyme USP42 promotes breast cancer progression by inhibiting JNK/p38-mediated apoptosis

Ubiquitin-specific Protease 4 Promotes Hepatocellular Carcinoma Progression Via Cyclophilin A Stabilization and Deubiquitination.